Diagnosis and Management of Infertility

Carson, Sandra Ann; Kallen, Amanda N.

doi:10.1001/jama.2021.4788

Cited by 434 publications

(313 citation statements)

References 101 publications

Supporting

Mentioning

251

Contrasting

Unclassified

Order By: Relevance

“…However, patients still commonly prefer medication first, striving for natural conception, and non-invasive drug interventions are often empirically applied prior to more advanced technologies ( Buckett and Sierra, 2019 ). Since the 1970s, various drugs have been used in the treatment of male infertility, including gonadotrophins, anti-estrogens, testosterone, anti-oxidation, and trace elements ( Li, 2014 ; Carson and Kallen, 2021 ). Although the pathological and physiological basis of idiopathic male infertility has not been elucidated clearly and no strong evidence supporting drug treatment in male infertility is available ( Minhas et al, 2021 ), we should not stop our discovery in proving drug effectiveness, and more rigorous investigations should be advocated and encouraged.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Poor Sperm Quality and Erectile Dysfunction With Oral Pentoxifylline: A Systematic Review

Lü

Zhang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Pentoxifylline (PTX) is a member of methylxanthine chemicals and a type of non-selective phosphodiesterase-5 inhibitors, which has been used in male infertility treatment to improve sperm quality and erectile dysfunction (ED) treatment. Mutually tight associations existed between ED and male infertility. Using PTX might kill two birds with one stone by improving sperm quality and erectile function in infertile men with ED.Methods: PubMed, Cochrane Library, EMBASE, and Web of Science were searched by October 2021. Based on available evidence from observational studies and randomized-controlled trials (RCTs), we conducted a systematic review to summarize the efficacy and safety of PTX in treating ED and male infertility. The protocol of the article was registered and updated in PROSPERO (CRD42021291396).Results: From 202 records, eight studies (7 RCTs) evaluating the role of PTX in ED and three studies (2 RCTs) assessing the efficacy of PTX in male infertility were included in the systematic review. Three studies (100.00%) and two studies (100.00%) reported the beneficial role of PTX in improving sperm progressive motility and normal sperm morphology rate, respectively. In contrast, only one study (33.33%) indicated the favorable role of PTX in enhancing sperm concentration. As for ED, three (60.00%) studies supported the treatment role of PTX alone in ED, and two studies (66.67%) favored the combination use of PTX and selective PDE5Is compared with selective PDE5Is alone. Safety analysis showed that PTX was a well-tolerated drug in ED and male infertility treatment.Conclusion: Given the association between ED and male infertility and satisfying findings from available evidence, PTX administration for the simultaneous treatment of poor sperm quality and mild ED in infertile men will highly enhance the treatment compliance. However, the finding should be treated carefully until validated by further studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of Poor Sperm Quality and Erectile Dysfunction With Oral Pentoxifylline: A Systematic Review

Lü

Zhang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The most common cause of female infertility is ovulatory dysfunction. Ovulatory disorders account for approximately 25% of infertility diagnoses; 70% of women with anovulation have PCOS [7]. Such a syndrome is a multifactorial disorder and is characterized by a combination of clinical (anovulation and hyperandrogenism), biochemical (excessive androgen and luteinizing hormone concentrations), and ovarian morphological (polycystic ovaries) features [8].…”

Section: Introductionmentioning

confidence: 99%

Dietary Supplements for Female Infertility: A Critical Review of Their Composition

et al. 2021

View full text Add to dashboard Cite

Infertility is the condition of about 15% of couples that cannot get a conception after one year of unprotected sexual intercourse. In females, the reduced reproductive capacity underlies the most varied causes. Dietary supplements (DS) might be used to improve the pregnancy rate and a wide range of DS are proposed today to support female fertility. Although many authors demonstrated the positive effect of some of these products, the real efficacy of this approach is still debated. In order to evaluate the potential efficacy of DS for female infertility, we analysed the products marketed in Italy, using an original approach. A review of literature was performed to evaluate the effect of nutraceuticals on various female reproductive outcomes and to detect the minimal effective daily dose (mED) able to improve at least one of these. Thereafter, we conceived a formula to classify the expected efficacy of each DS. Each DS was scored and included into three classes of expected efficacy: higher, lower, and none. Ten out of 24 supplements (41.7%) resulted in the higher and 8 (34.3%) in the lower efficacy group, the remaining 6 DS (25.0%) were expected to have no efficacy. DS marketed in Italy are usually blends of many substances that are frequently employed at a negligible dose or without any evidence of efficacy. These findings raise serious doubt about the potential effectiveness of most commercial DS for female infertility.

show abstract

“…Testosterone secretion by Leydig cells makes a major contribution to the control of sperm maturation and male fertility [ 24 , 25 , 26 ]. However, the use of gonadotropins in the clinic for the treatment of hypogonadotropic hypogonadism, delayed puberty in boys and age-related androgen deficiency often leads to side effects [ 27 , 28 , 29 ]. This may be due to structural differences between the gonadotropin preparations (recombinant LH, recombinant and urinary hCG), which changes the effectiveness of their stimulating effect on various intracellular cascades and effector proteins [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

The Effects of Separate and Combined Treatment of Male Rats with Type 2 Diabetes with Metformin and Orthosteric and Allosteric Agonists of Luteinizing Hormone Receptor on Steroidogenesis and Spermatogenesis

Bakhtyukov

Derkach

Sorokoumov

et al. 2021

IJMS

View full text Add to dashboard Cite

In men with type 2 diabetes mellitus (T2DM), steroidogenesis and spermatogenesis are impaired. Metformin and the agonists of luteinizing hormone/human chorionic gonadotropin(hCG)-receptor (LH/hCG-R) (hCG, low-molecular-weight allosteric LH/hCG-R-agonists) can be used to restore them. The aim was to study effectiveness of separate and combined administration of metformin, hCG and 5-amino-N-tert-butyl-2-(methylsulfanyl)-4-(3-(nicotinamido)phenyl)thieno[2,3-d]pyrimidine-6-carboxamide (TP3) on steroidogenesis and spermatogenesis in male rats with T2DM. hCG (15 IU/rat/day) and TP3 (15 mg/kg/day) were injected in the last five days of five-week metformin treatment (120 mg/kg/day). Metformin improved testicular steroidogenesis and spermatogenesis and restored LH/hCG-R-expression. Compared to control, in T2DM, hCG stimulated steroidogenesis and StAR-gene expression less effectively and, after five-day administration, reduced LH/hCG-R-expression, while TP3 effects changed weaker. In co-administration of metformin and LH/hCG-R-agonists, on the first day, stimulating effects of LH/hCG-R-agonists on testosterone levels and hCG-stimulated expression of StAR- and CYP17A1-genes were increased, but on the 3–5th day, they disappeared. This was due to reduced LH/hCG-R-gene expression and increased aromatase-catalyzed estradiol production. With co-administration, LH/hCG-R-agonists did not contribute to improving spermatogenesis, induced by metformin. Thus, in T2DM, metformin and LH/hCG-R-agonists restore steroidogenesis and spermatogenesis, with metformin being more effective in restoring spermatogenesis, and their co-administration improves LH/hCG-R-agonist-stimulating testicular steroidogenesis in acute but not chronic administration.

show abstract

Diagnosis and Management of Infertility

Cited by 434 publications

References 101 publications

Treatment of Poor Sperm Quality and Erectile Dysfunction With Oral Pentoxifylline: A Systematic Review

Treatment of Poor Sperm Quality and Erectile Dysfunction With Oral Pentoxifylline: A Systematic Review

Dietary Supplements for Female Infertility: A Critical Review of Their Composition

The Effects of Separate and Combined Treatment of Male Rats with Type 2 Diabetes with Metformin and Orthosteric and Allosteric Agonists of Luteinizing Hormone Receptor on Steroidogenesis and Spermatogenesis

Contact Info

Product

Resources

About